表紙
市場調査レポート

院内感染型MRSA (メチシリン耐性黄色ブドウ球菌) 感染症:パイプライン製品の分析

Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Pipeline Review, H1 2016

発行 Global Markets Direct 商品コード 288828
出版日 ページ情報 英文 46 Pages
即納可能
価格
本日の銀行送金レート: 1USD=105.42円で換算しております。
Back to Top
院内感染型MRSA (メチシリン耐性黄色ブドウ球菌) 感染症:パイプライン製品の分析 Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Pipeline Review, H1 2016
出版日: 2016年06月08日 ページ情報: 英文 46 Pages
概要

メチシリン耐性黄色ブドウ球菌(MRSA)には、メチシリンを含む一部の抗生物質に対する耐性を備えているため、殺菌が難しいという特徴があります。また、MRSAは往々にして、病院・医療機関での治療行為と関連付けられています。主な疾病素質として、現在入院中であること、侵襲性の医療機器を使用していること、長期間にわたり入院していることなどが挙げられます。衛生手続を遵守するで、この細菌への感染リスクを軽減することができます。

当レポートでは、世界各国での院内感染型MRSA (メチシリン耐性黄色ブドウ球菌) 感染症治療用のパイプライン製品の開発状況について分析し、製品開発・上市の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要、最新の業界動向などの情報をお届けします。

イントロダクション

  • 調査範囲

院内感染型MRSA (メチシリン耐性黄色ブドウ球菌) 感染症:パイプライン製品の分析の概要

治療薬の開発

  • パイプライン製品の概要
  • パイプライン製品の比較分析

院内感染型MRSA (メチシリン耐性黄色ブドウ球菌) 感染症:パイプライン製品の分析:企業で開発中の治療薬

院内感染型MRSA (メチシリン耐性黄色ブドウ球菌) 感染症:パイプライン製品の分析:大学/機関で研究中の治療薬

院内感染型MRSA (メチシリン耐性黄色ブドウ球菌) 感染症:パイプライン製品の分析:パイプライン製品の概況

  • 臨床段階の製品
  • 初期段階の製品

院内感染型MRSA (メチシリン耐性黄色ブドウ球菌) 感染症:パイプライン製品の分析:企業で開発中の製品

院内感染型MRSA (メチシリン耐性黄色ブドウ球菌) 感染症:パイプライン製品の分析:大学/機関で研究中の製品

院内感染型MRSA (メチシリン耐性黄色ブドウ球菌) 感染症:パイプライン製品の分析の治療薬開発に従事している企業

  • Destiny Pharma Limited
  • Galapagos NV
  • MGB Biopharma Limited
  • Syntiron LLC
  • Techulon, Inc.

院内感染型MRSA (メチシリン耐性黄色ブドウ球菌) 感染症:パイプライン製品の分析:治療薬の評価

  • 単剤製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

院内感染型MRSA (メチシリン耐性黄色ブドウ球菌) 感染症:パイプライン製品の分析:最近のパイプライン動向

院内感染型MRSA (メチシリン耐性黄色ブドウ球菌) 感染症:パイプライン製品の分析:休止中のプロジェクト

院内感染型MRSA (メチシリン耐性黄色ブドウ球菌) 感染症:パイプライン製品の分析:開発が中止された製品

院内感染型MRSA (メチシリン耐性黄色ブドウ球菌) 感染症:パイプライン製品の分析:製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC8208IDB

Summary

Global Markets Direct's, 'Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Pipeline Review, H1 2016', provides an overview of the Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections
  • The report reviews pipeline therapeutics for Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections therapeutics and enlists all their major and minor projects
  • The report assesses Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections Overview
  • Therapeutics Development
    • Pipeline Products for Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Overview
    • Pipeline Products for Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Comparative Analysis
  • Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Therapeutics under Development by Companies
  • Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Therapeutics under Investigation by Universities/Institutes
  • Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
  • Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Products under Development by Companies
  • Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Products under Investigation by Universities/Institutes
  • Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Companies Involved in Therapeutics Development
    • Destiny Pharma Limited
    • Galapagos NV
    • MGB Biopharma Limited
    • Syntiron LLC
    • Techulon, Inc.
  • Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • acALY-18 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Antisense Oligonucleotide for Hospital Acquired MRSA - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • exeporfinium chloride - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • GLPG-1492 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MGBBP-3 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MH-003 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Peptides to Disrupt Cell Membrane for Infectious Diseases - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Siderocillin - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Staphylococcus aureus vaccine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Recent Pipeline Updates
  • Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Dormant Projects
  • Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Discontinued Products
  • Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Product Development Milestones
    • Featured News & Press Releases
      • Jun 02, 2015: MGB Biopharma Succeeds in Developing an IV Formulation of MGB-BP-3 for the Treatment of Systemic Susceptible and Resistant Gram-Positive Hospital-Acquired Infections
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections, H1 2016
  • Number of Products under Development for Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Products under Investigation by Universities/Institutes, H1 2016
  • Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Pipeline by Destiny Pharma Limited, H1 2016
  • Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Pipeline by Galapagos NV, H1 2016
  • Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Pipeline by MGB Biopharma Limited, H1 2016
  • Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Pipeline by Syntiron LLC, H1 2016
  • Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Pipeline by Techulon, Inc., H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections Therapeutics - Recent Pipeline Updates, H1 2016
  • Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Dormant Projects, H1 2016
  • Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Discontinued Products, H1 2016

List of Figures

  • Number of Products under Development for Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections, H1 2016
  • Number of Products under Development for Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Targets, H1 2016
  • Number of Products by Stage and Targets, H1 2016
  • Number of Products by Mechanism of Actions, H1 2016
  • Number of Products by Stage and Mechanism of Actions, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Molecule Types, H1 2016
  • Number of Products by Stage and Molecule Types, H1 2016
Back to Top